Novel therapies for hypereosinophilic syndromes

Netherlands Journal of Medicine

Volumn 68, Issue 7-8, 2010, Pages 304-310

  Antoniu, S A ^a  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Alemtuzumab; Anti IL 5 monoclonal antibodies; Hypereosinophilic syndromes; Tyrosine kinase inhibitors

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; CORTICOSTEROID; DASATINIB; IMATINIB; MEPOLIZUMAB; MIDOSTAURIN; MONOCLONAL ANTIBODY; NILOTINIB; RESLIZUMAB; SORAFENIB;

ALLOGENIC BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG EFFICACY; EOSINOPHIL COUNT; EOSINOPHILIA; HUMAN; HYPEREOSINOPHILIC SYNDROME; NONHUMAN; PROTEIN EXPRESSION; REMISSION; REVIEW; TREATMENT RESPONSE;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; BONE MARROW TRANSPLANTATION; GLYCOPROTEINS; HUMANS; HYPEREOSINOPHILIC SYNDROME; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; INTERLEUKIN-5; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIDINES; PYRIMIDINES;

EID: 77957735970     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Pardanani A, Tefferi A. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood. 2004;104(7):1931-1939.
2. Chusid MJ, West BC, Wolff SM. The hypereosinophilic syndromes: analysis of fourteen cases with review of literature. Medicine (Baltimore). 1975;54(1):1-27.
3. Idiopathic hypereosinophilic syndrome. http://www.orpha.net/data/patho/GB/uk-IdiopHypereosinophSyndr.pdf (2004).
4. Klion AD. Recent advances in the diagnosis and treatment of hypereosinophilic syndromes. Hematology. 2005;1:209-214.
5. Gotlib J. Chronic eosinophilic leukemia/hypereosinophilic syndrome. Cancer Treat Res. 2008;142:69-106.
6. Kahn JE, Bletry O, Guillevin L. Hypereosinophilic syndromes. Best Pract Res Clin Rheumatol. 2008;22(5):863-882.
7. Kalac M, Quintas-Cardama A, Vrhovac R, Kantarjian H, Verstovsek S. A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. Cancer. 2007;110(5):955-964.
8. Aldebert D, Lamkhioued B, Desaint C, et al. Eosinophils express a functional receptor for interferon alpha: inhibitory role of interferon alpha on the release of mediators. Blood. 1996;87(6):2354-2360.
9. Butterfield JH. Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. Acta Haematol. 2005;114(1):26-40.
10. Schandene L, Cogan E, Crusiaux A, Goldman M. Interferon-alpha upregulates both interleukin-10 and interferon-gamma production by human CD4+ T cells. Blood. 1997;89(3):1110-1111.
11. Schandene L, Del Prete GF, Cogan E, et al. Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4+ T cells. J Clin Invest. 1996;97(2):309-315.
12. Schoffski P, Ganser A, Pascheberg U, et al. Complete haematological and cytogenetic response to interferon alpha-2a of a myeloproliferative disorder with eosinophilia associated with a unique t(4;7) aberration. Ann Hematol. 2000;79(2):95-98.
13. Ceretelli S, Capochiani E, Petrini M. Interferon-alpha in the idiopathic hypereosinophilic syndrome: consideration of five cases. Ann Hematol. 1998;77(4):161-164.
14. Butterfield JH, Gleich GJ. Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Intern Med. 1994;121(9):648-653.
15. Demiroglu H, Dundar S. Combination of interferon-alpha and hydroxyurea in the treatment of idiopathic hypereosinophilic syndrome. Br J Haematol. 1997;97(4):928-930.
16. Ueno NT, Anagnostopoulos A, Rondon G, et al. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol. 2002;119(1):131-134.
17. Cooper MA, Akard LP, Thompson JM, Dugan MJ, Jansen J. Hypereosinophilic syndrome: long-term remission following allogeneic stem cell transplant in spite of transient eosinophilia post-transplant. Am J Hematol. 2005;78(1):33-36.
18. Cools J, Deangelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348(13):1201-1214.
19. http://www.fda.gov/cder/foi/label/2003/021588s002lbl.pdf.
20. Jones RL, Judson IR. The development and application of imatinib. Expert Opin Drug Saf. 2005;4(2):183-191.
21. Schaller JL, Burkland GA. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed. 2001;3(5):9.
22. Ault P, Cortes J, Koller C, Kaled ES, Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res. 2002;26(9):881-884.
23. Cortes J, Ault P, Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003;101(12):4714-4716.
24. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002;359(9317):1577-1578.
25. Frickhofen N, Marker-Hermann E, Reiter A, et al. Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib. Ann Hematol. 2004;83(7):477-480.
26. Klion AD, Robyn J, Akin C, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. 2004;103(2):473-478.
27. Martinelli G, Malagola M, Ottaviani E, et al. Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome. Haematologica. 2004;89(2):236-237.
28. Pardanani A, Reede R T, Porrata LF, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 2003;101(9):3391-3397.
29. Rose C, Dupire S, Roche-Lestienne C, et al. Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft. Leukemia. 2004;18(2):354-355.
30. Vandenberghe P, Wlodarska I, Michaux L, et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia. 2004;18(4):734-742.
31. Elliott MA, Pardanani A, Li CY, Tefferi A. Immunophenotypic normalization of aberrant mast cells accompanies histological remission in imatinib-treated patients with eosinophilia-associated mastocytosis. Leukemia. 2004;18(5):1027-1029.
32. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7(2):129-141.
33. Von Bubnoff N, Gorantla SP, Thone S, Peschel C, Duyster J. The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib). Blood. 2006;107(12):4970-4971; author reply 4972.
34. Verstovsek S, Giles FJ, Quintas-Cardama A, et al. Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells. Leuk Res. 2006;30(12):1499-1505.
35. Stover EH, Chen J, Lee BH, et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood. 2005;106(9):3206-3213.
36. Le Coutre P, Hochhaus A, Heim D, et al. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to patients with hypereosiniphilic syndrome (HES). ASH Ann Meeting Abstr. 2006;108(11):4912.
37. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099-7109.
38. Lierman E, Folens C, Stover EH, et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood. 2006;108(4):1374-1376.
39. Lierman E, MIchaux L, Beullens E, et al. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia. 2009;23(5):845-851.
40. Salemi S, Yousefi S, Simon D, et al. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome. Allergy. 2009;64(6):913-918.
41. Andrejauskas-Buchdunger E, Regenass U. Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251. Cancer Res. 1992;52(19):5353-5358.
42. Cools J, Stover EH, Boulton CL, et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease. Cancer Cell. 2003;3(5):459-469.
43. Fabbro D, Ruetz S, Bodis S, et al. PKC412--a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des. 2000;15(1):17-28.
44. Schade AE, Schieven GL, Townsend R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood. 2008;111(3):1366-1377.
45. Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006;66(1):473-481.
46. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinibresistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354(24):2531-2541.
47. Cogan E, Schandene L, Crusiaux A, et al. Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med. 1994;330(8):535-538.
48. Ravoet M, Sibille C, Roufosse F, et al. 6q- is an early and persistent chromosomal aberration in CD3-CD4+ T-cell clones associated with the lymphocytic variant of hypereosinophilic syndrome. Haematologica. 2005;90(6):753-765.
49. Takatsu K, Nakajima H. IL-5 and eosinophilia. Curr Opin Immunol. 2008;20(3):288-294.
50. Antoniu SA. Cytokine antagonists for the treatment of asthma: progress to date. BioDrugs. 2009;23(4):241-251.
51. Zhang J, Kuvelkar R, Murgolo NJ, et al. Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5. Int Immunol. 1999;11(12):1935-1944.
52. Klion AD, Law MA, Noel P, et al. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood. 2004;103(8):2939-2941.
53. Kim YJ, Prussin C, Martin B, et al. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. J Allergy Clin Immunol. 2004;114(6):1449-1455.
54. Kips JC, O'Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med. 2003;167(12):1655-1659.
55. Koury MJ, Newman JH, Murray JJ. Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib. Am J Med. 2003;115(7):587-589.
56. Plotz S-G, Simon H-U, Darsow U, et al. Use of an Anti-Interleukin-5 Antibody in the Hypereosinophilic Syndrome with Eosinophilic Dermatitis. N Engl J Med. 2003;349(24):2334-2339.
57. Garrett JK, Jameson SC, Thomson B, et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol. 2004;113(1):115-119.
58. Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008;358(12):1215-1228.
59. Stein ML, Villanueva JM, Buckmeier BK, et al. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol. 2008;121(6):1473-1483, 1483, e1471-e1474.
60. Press Release. GlaxoSmithKline withdraws its marketing authorization application for Bosatria (mepolizumab). (2009) (Doc. Ref. EMEA/483760/2009) EMEA.
61. Elsner J, Hochstetter R, Spiekermann K, Kapp A. Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood. 1996;88(12):4684-4693.
62. Sefcick A, Sowter D, Dasgupta E, Russell NH, Byrne JL. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome. Br J Haematol. 2004;124(4):558-559.
63. Pitini V, Teti D, Arrigo C, Righi M. Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report. Br J Haematol. 2004;127(5):477.
64. Quintas-Cardama ATA, Cortes J, et al. Alemtuzumab (CAMPATH-1HTM) is effective therapy for hypereosinophilic syndrome (HES). Blood. 2006;108:Abstract 4902.
65. Verstovsek S, Tefferi A, Kantarjian H, et al. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res. 2009;15(1):368-373.